MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Immunosuppressants - GI

Drug Safety Update

  April 2014: There is an increased risk of tuberculosis, or reactivation of latent tuberculosis, during treatment with tumour necrosis factor alpha (TNF-alpha) inhibitors. TNF-alpha inhibitors are contraindicated in patients with active tuberculosis or other severe infections.

 January 2015: Ustekinumab (Stelara): risk of exfoliative dermatitis

NICE Guidance (also see drug-specific NICE links below)

CG 152: Crohn's disease, October 2012

TA 633: Ustekinumab for treating moderately to severely active ulcerative colitis, June 2020